Change of habit might be key to drug's success  To turn its new multiple sclerosis treatment Antegren into a blockbuster drug with more than \$1 billion in annual sales, Biogen Idec and its partner, Elan Pharmaceuticals, might not have to persuade doctors that it is superior to existing interferon treatments. Partial data released by the companies appear to confirm the treatment's outstanding clinical performance.